Table. Testing Results for NOS Samples Obtained at COVID-19 Diagnosis or After COVID-19 Recovery in 32 Study Patientsa.
| Sample | COVID-19 samples tested | Days of recovery sampling since diagnosis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | Recovery | |||||||||||
| Genomic RNA (CT value) | Subgenomic RNA (CT value) | Genomic RNA (CT value) | Subgenomic (CT value) | RNA load, copies/mL | Serology (positive or negative result) | |||||||
| Sample No. | E gene | RdRP gene | N gene | E gene | E gene | RdRP gene | N gene | E gene | N gene | IgG | IgA | |
| 1 | 31.6 | 31.3 | 31.2 | 34.5 | 29.3 | 30.7 | 31.2 | 39.1 | 1.2 × 104 | Positive | Positive | 39 |
| 2 | 27.0 | 26.9 | 30.0 | 36.0 | 30.0 | 30.5 | 31.2 | NA | 8.9 × 103 | Positive | Positive | 31 |
| 3 | 19.3 | 20.8 | 22.1 | 35.2 | 31.5 | 34.7 | 32.8 | 3.3 × 103 | Positive | Negative | 44 | |
| 4 | 21.6 | 22.0 | 22.9 | 36.4 | 31.8 | 31.4 | 32.3 | 5.5 × 103 | Positive | Positive | 34 | |
| 5 | 30.0 | 32.8 | 38.1 | 30.2 | 31.8 | 34.3 | 34.5 | 3.2 × 103 | Positive | Positive | 62 | |
| 6 | 20.8 | 20.9 | 22.3 | 37.3 | 32.2 | 32.8 | 34.1 | 5.3 × 103 | Positive | Positive | 37 | |
| 7 | 27.3 | 29.9 | 31.3 | 36.9 | 32.3 | 30.9 | 32.7 | 6.4 × 103 | Positive | Positive | 39 | |
| 8 | 26.9 | 27.0 | 31.2 | 38.1 | 35.0 | 34.4 | 36.1 | 4.0 × 102 | Positive | Positive | 71 | |
| 9 | 22.5 | 23.7 | 24.9 | 31.0 | 38.8 | 33.6 | 33.9 | 2.6 × 103 | Negative | Negative | 42 | |
| 10 | 21.3 | 21.4 | 28.9 | 38.9 | NA | 32.2 | 33.4 | 1.2 × 104 | Positive | Positive | 56 | |
| 11 | 26.6 | 26.9 | 28.1 | 33.0 | 32.8 | 33.2 | 1.3 × 104 | Positive | Positive | 54 | ||
| 12 | 22.8 | 24.2 | 25.3 | 31.0 | 34.2 | 33.7 | 6.9 × 103 | Positive | Positive | 55 | ||
| 13 | 25.8 | 25.8 | 26.1 | 39.8 | 34.8 | 39.1 | 3.0 × 102 | Positive | Positive | 36 | ||
| 14 | 20.8 | 20.4 | 21.1 | 32.0 | 35.0 | 35.1 | 1.9 × 103 | Positive | Positive | 56 | ||
| 15 | 29.4 | 30.1 | 32.2 | 37.0 | 36.5 | 39.2 | 3.2 × 103 | Positive | Positive | 36 | ||
| 16 | 27.9 | 29.1 | 31.1 | 32.0 | 38.1 | 39.3 | 1.6 × 101 | Positive | Positive | 77 | ||
| 17 | 30.6 | 29.9 | 31.8 | 32.1 | NA | 35.7 | 5.4 × 103 | Positive | Positive | 53 | ||
| 18 | 28.5 | 29.1 | 30.8 | 36.8 | 36.8 | 2.9 × 103 | Positive | Positive | 43 | |||
| 19 | 26.9 | 22.2 | 26.1 | 30.1 | 37.5 | 1.1 × 103 | Positive | Positive | 36 | |||
| 20 | 25.7 | 25.2 | 28.9 | 38.0 | 37.9 | 2.6 × 103 | Positive | Positive | 48 | |||
| 21 | 27.0 | 29.0 | 30.2 | 32.3 | 38.1 | 1.9 × 103 | Positive | Positive | 41 | |||
| 22 | 28.5 | 29.4 | 30.0 | 32.3 | 38.4 | 4.9 × 101 | Positive | Negative | 76 | |||
| 23 | 27.1 | 28.6 | 29.3 | 36.1 | 38.9 | 4.5 × 102 | Positive | Positive | 29 | |||
| 24 | 25.4 | 22.9 | 24.1 | 34.8 | 39.0 | 5.6 × 101 | Positive | Positive | 70 | |||
| 25 | 28.7 | 29.5 | 31.4 | 37.3 | 39.1 | 5.4 × 103 | Negative | Positive | 46 | |||
| 26 | 27.1 | 27.7 | 29.2 | 37.1 | 39.1 | 1.9 × 103 | Positive | Positive | 34 | |||
| 27 | 26.7 | 27.7 | 29.6 | 39.2 | 39.2 | 2.0 × 103 | Positive | Positive | 45 | |||
| 28 | 17.1 | 19.1 | 19.9 | 33.0 | 39.2 | 8.5 × 102 | Positive | Positive | 40 | |||
| 29 | 27.0 | 28.9 | 30.0 | 32.1 | 39.3 | 5.0 × 101 | Positive | Positive | 56 | |||
| 30 | 22.9 | 23.8 | 25.8 | 37.1 | 39.4 | 1.6 × 102 | Positive | Positive | 55 | |||
| 31 | 28.6 | 30.4 | 30.9 | 33.0 | 39.6 | 5.3 × 102 | Positive | Positive | 61 | |||
| 32 | 29.1 | 28.0 | 30.9 | 36.2 | 39.8 | 3.4 × 102 | Positive | Positive | 53 | |||
Abbreviations: COVID-19, coronavirus disease 2019; CT, cycle threshold; E gene, envelope gene; NA, not applicable; N gene, nucleocapsid gene; RdRP, RNA-dependent RNA polymerase; RT-PCR, real-time polymerase chain reaction.
For RT-PCR testing, the Seegene Allplex 2019-nCoV and Clonit Quanty COVID-19 assays were used for total RNA detection and quantification, respectively, whereas replicative (E gene) RNA was detected by an in-house RT-PCR assay.4 Results were expressed as CT values (<40 for positive detection) or quantified as RNA (N gene) copies per mL. NA indicates the absence of positive detection for the indicated gene. For serological testing, SARS-CoV-2 IgG/IgA Euroimmun enzyme-linked immunoassays were used, and positive and negative results were assessed using the 1.1 or greater or less than 1.1 times the manufacturer’s cutoffs as reference IgG/IgA values, respectively.